BREAKWATER safety lead-in (SLI): Encorafenib + cetuximab (EC) ± chemotherapy for first-line (1L) treatment (tx) of BRAF V600E-mutant (BRAF V600E) metastatic colorectal cancer (mCRC).
| Publicado en: | Journal of Clinical Oncology Vol. 40; pp. 134 - 135 |
|---|---|
| Autores principales: | , , , , , , , , , , , , , |
| Formato: | Journal Article |
| Publicado: |
American Society of Clinical Oncology
1/6/2022 Supplement
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=183147573&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 183147573 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 0732183X 20D jtl: Journal of Clinical Oncology issn: 0732183X maglogo: N pubinfo: dt: 1/6/2022 Supplement vid: 40 pid: 26892 pub: American Society of Clinical Oncology place: Alexandria, Virginia artinfo: ui: 183147573 10.1200/JCO.2022.40.4_suppl.134 183147573 ppf: 134 ppct: 1 formats: tig: atl: BREAKWATER safety lead-in (SLI): Encorafenib + cetuximab (EC) ± chemotherapy for first-line (1L) treatment (tx) of BRAF V600E-mutant (BRAF V600E) metastatic colorectal cancer (mCRC). aug: au: Kopetz, Scott Yoshino, Takayuki Kim, Tae Won Desai, Jayesh Yaeger, Rona Van Cutsem, Eric Ciardiello, Fortunato Wasan, Harpreet Singh Maughan, Tim Zhang, Yuanyuan Usari, Tiziana Chung, Chin-Hee Zhang, Xiaosong Tabernero, Josep affil: MD Anderson Cancer Center, Houston, TX sug: pubtype: Academic Journal doctype: Journal Article ougenre: Article ab: language: English refInfo: holdings: @attributes: islocal: N |
|---|